Actively Recruiting
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Led by Sun Yat-sen University · Updated on 2024-09-26
35
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
CONDITIONS
Official Title
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with laryngeal cancer (T3-4N0-3M0) or hypopharyngeal cancer (T2-4N0-3M0) staged by AJCC 8th edition
- Aged between 18 and 70 years
- Performance status score of 0 or 1
- Normal organ function to tolerate chemotherapy, immunotherapy, and radiotherapy
You will not qualify if you...
- Having other malignant tumors besides the laryngeal or hypopharyngeal cancer
- Contraindications to immunotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
F
Fang-Yun Xie
CONTACT
D
Dian OuYang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here